Total Payments
$6,357
2024 Payments
$529.10
Companies
44
Transactions
430
Medicare Patients
7,030
Medicare Billing
$332,257
Payment Breakdown by Category
Food & Beverage$6,357 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,357 | 430 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $796.53 | 49 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $771.50 | 61 | $0 (2024) |
| PFIZER INC. | $636.55 | 51 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $564.71 | 37 | $0 (2023) |
| Amgen Inc. | $522.84 | 41 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $429.64 | 36 | $0 (2023) |
| HEARTFLOW, INC. | $380.78 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $358.26 | 31 | $0 (2023) |
| Gilead Sciences, Inc. | $206.49 | 17 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $170.98 | 12 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $529.10 | 15 | HEARTFLOW, INC. ($323.06) |
| 2023 | $1,159 | 68 | PFIZER INC. ($201.33) |
| 2022 | $878.10 | 52 | Janssen Pharmaceuticals, Inc ($142.09) |
| 2021 | $146.07 | 2 | Janssen Pharmaceuticals, Inc ($124.77) |
| 2020 | $187.12 | 14 | E.R. Squibb & Sons, L.L.C. ($47.50) |
| 2019 | $1,215 | 96 | Amgen Inc. ($170.11) |
| 2018 | $1,102 | 93 | Janssen Pharmaceuticals, Inc ($154.42) |
| 2017 | $1,140 | 90 | Novartis Pharmaceuticals Corporation ($183.73) |
All Payment Transactions
430 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $33.55 | General |
| Category: Coronary | ||||||
| 11/04/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Cardiology | ||||||
| 10/29/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $31.40 | General |
| Category: Coronary | ||||||
| 09/16/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/27/2024 | ShockWave Medical, Inc | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter (Device) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Lithoplasty | ||||||
| 08/26/2024 | Recor Medical Inc | PARADISE RENAL DENERVATION SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $17.89 | General |
| Category: Endovascular | ||||||
| 08/19/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: Cardiology | ||||||
| 06/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/03/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/02/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: Not Applicable | ||||||
| 04/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/21/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $258.11 | General |
| Category: Coronary | ||||||
| 02/29/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: Cardiology | ||||||
| 02/01/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/11/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/06/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $28.70 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/30/2023 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $10.81 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/28/2023 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Genetic Disease | ||||||
| 11/27/2023 | PFIZER INC. | VYNDAQEL (Drug), COMIRNATY | Food and Beverage | In-kind items and services | $13.01 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/01/2023 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/30/2023 | HeartFlow, Inc. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $19.68 | General |
| Category: Coronary | ||||||
| 10/25/2023 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $15.18 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/24/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $13.19 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/19/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/19/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,690 | 1,835 | $190,248 | $70,022 |
| 2022 | 22 | 1,548 | 1,694 | $196,426 | $75,029 |
| 2021 | 24 | 1,859 | 2,153 | $258,796 | $103,929 |
| 2020 | 24 | 1,933 | 2,154 | $220,227 | $83,277 |
Total Patients
7,030
Total Services
7,836
Medicare Billing
$332,257
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 193 | 229 | $40,487 | $18,416 | 45.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 298 | 303 | $45,450 | $14,597 | 32.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 45 | 45 | $11,205 | $4,726 | 42.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 85 | 90 | $11,162 | $4,717 | 42.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 88 | 88 | $16,544 | $4,607 | 27.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 42 | 45 | $9,360 | $4,122 | 44.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 53 | 71 | $7,739 | $3,843 | 49.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $6,260 | $3,024 | 48.3% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 297 | 371 | $7,420 | $2,154 | 29.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 12 | $2,760 | $1,594 | 57.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 165 | 167 | $6,680 | $1,513 | 22.7% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Facility | 2023 | 29 | 29 | $5,887 | $1,509 | 25.6% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 95 | 95 | $5,035 | $1,376 | 27.3% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 95 | 95 | $3,230 | $915.37 | 28.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 11 | $3,100 | $839.07 | 27.1% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 29 | 31 | $1,891 | $560.70 | 29.7% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Facility | 2023 | 27 | 27 | $1,674 | $470.75 | 28.1% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 29 | 29 | $1,276 | $347.48 | 27.2% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Facility | 2023 | 29 | 29 | $1,856 | $338.04 | 18.2% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Facility | 2023 | 16 | 16 | $880.00 | $282.40 | 32.1% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 32 | 32 | $352.00 | $70.20 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 198 | 247 | $40,261 | $21,069 | 52.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 251 | 254 | $38,100 | $11,995 | 31.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 46 | $10,481 | $5,658 | 54.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 34 | $10,438 | $5,039 | 48.3% |
About Dr. Ibad Ansari, MD
Dr. Ibad Ansari, MD is a Specialist healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245219997.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ibad Ansari, MD has received a total of $6,357 in payments from pharmaceutical and medical device companies, with $529.10 received in 2024. These payments were reported across 430 transactions from 44 companies. The most common payment nature is "Food and Beverage" ($6,357).
As a Medicare-enrolled provider, Ansari has provided services to 7,030 Medicare beneficiaries, totaling 7,836 services with total Medicare billing of $332,257. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Cardiovascular Disease
- Location Indianapolis, IN
- Active Since 01/11/2006
- Last Updated 06/11/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1245219997
Products in Payments
- XARELTO (Drug) $796.53
- ELIQUIS (Drug) $740.28
- ENTRESTO (Drug) $631.59
- BRILINTA (Drug) $435.51
- FFRct (Device) $380.78
- Repatha (Biological) $312.24
- MULTAQ (Drug) $264.96
- Corlanor (Drug) $210.60
- PRALUENT (Drug) $164.68
- VERQUVO (Drug) $157.20
- CHANTIX (Drug) $149.56
- LEQVIO (Drug) $139.91
- FARXIGA (Drug) $129.20
- Indigo (Device) $106.67
- LifeVest (Device) $106.01
- PRALUENT ALIROCUMAB INJECTION (Biological) $94.77
- PRADAXA (Drug) $83.03
- VYNDAQEL (Drug) $75.71
- Definity (Drug) $73.82
- NORTHERA (Drug) $71.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Indianapolis
Dr. Christopher Obeime, Md, MD
Specialist — Payments: $911,807
Specialist $911,807
Dr. David Muram, Md, MD
Specialist — Payments: $570,000
Specialist $570,000
Brian Mullis, Md, MD
Specialist — Payments: $547,817
Specialist $547,817
Dr. Bruce Van Natta, Md, MD
Specialist — Payments: $425,360
Specialist $425,360
Joachim Wernicke, Md, MD
Specialist — Payments: $412,683
Specialist $412,683
Eromonsele Idahosa, Md, MD
Specialist — Payments: $122,569
Specialist $122,569